anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Galantamine is rapidly and completely absorbed with time to peak concentration about 1 hour. Bioavailability of the tablet was the same as the bioavailability of an oral solution. Food did not affect the AUC of galantamine but Cmax decreased by 25% and Tmax was delayed by 1.5 hours. The mean volume of distribution of galantamine is 175 L.

The plasma protein binding of galantamine is 18% at therapeutically relevant concentrations. In whole blood, galantamine is mainly distributed to blood cells (52.7%). The blood to plasma concentration ratio of galantamine is 1.2.
Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
Psychotic-like experiences (PLEs) have been associated with poor sleep quality and increased suicide risk. However, the association between PLEs, insomnia and suicide risk has not been thoroughly investigated in prior studies. In this study, we aimed to explore as to whether insomnia moderates the association between PLEs and suicidal ideation. The study was performed in 4203 young adults (aged 18-35 years, 63.8% females). Data were collected using self-reports. Moderation analysis demonstrated that PLEs are associated with higher levels of the current suicidal ideation only in participants with greater severity of insomnia (B = 0.003, p < 0.001). This analysis included age, gender, education, occupation and depressive symptoms as covariates. Moreover, the network analysis demonstrated that nodes representing PLEs are connected to the node of current suicidal ideation only in participants with greater severity of insomnia. The nodes of PLEs connected to the current suicidal ideation node captured PLEs representing deja vu experiences, auditory hallucination-like experiences and paranoia (edge weights between 0.011 and 0.083). Furthermore, nodes representing PLEs were the three most central nodes in the network analysis of individuals with higher levels of insomnia (strength centrality between 0.96 and 1.10). In turn, the three most central nodes were represented by depressive symptoms in the network analysis of individuals with lower levels of insomnia (strength centrality between 0.67 and 0.79). Findings from this study indicate that insomnia might be an important risk factor of suicide in people with PLEs, especially those reporting deja vu experiences, auditory hallucination-like experiences and paranoia.
PROBLEM TO BE SOLVED: To provide the subject new polypeptide composed of a slit-formed polypeptide (or its mutant) containing a specific amino acid sequence, expressed in cerebral and nervous systems and giving an antibody useful. e.g. for the diagnosis and treatment of diseases of spinal cord, thyroid gland, ovary, heart, lymph gland, etc. SOLUTION: This new polypeptide consists of a slit-formed polypeptide containing an amino acid sequence described by the formula or its mutant. It is expressed in spinal cord and endocrine system. The antibody specifically recognizing the polypeptide is useful for the treatment, diagnosis, etc., of all diseases of spinal cord, thyroid gland, ovary, prostate gland, adrenal gland, small intestine, heart, trachea, thymus gland, lymph gland, muscular system and colon. The polypeptide can be produced by screening a human genom gene library or a cDNA library using a partial gene of a human slit-formed polypeptide as a probe, integrating the obtained human slit-formed polypeptide gene into a vector, introducing into a host cell and expressing in the cell.
A diagnosis of polymyositis can readily be made when there is a typical history of proximal muscle weakness together with clinical findings, and there is corroboratory evidence in the form of elevated creatine kinase lactate dehydrogenase, aldolase, and serum glutamic-oxaloacetic transaminase (aspartate aminotransferase). A muscle biopsy usually helps in making the confirmatory diagnosis. A female in her 50s presented with non-healing multiple deep necrotic ulcers with muscle weakness. The initial possibility of vasculitis ulcers remained. Later, this proved to be a case of polymyositis with mildly elevated creatine kinase (which is usually not the case), atypical skin manifestations (usually there is no skin involvement), and negative extended myositis specific antibody panel with the growth of Burkholderia cepacia (perhaps the triggering factor). Hence, polymyositis can present with a myriad of atypical findings. Thus, thorough clinical examination and an integrated approach are necessary for early identification and treatment of the disease.
The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. Each participant will practice from home, using a zoom system. The duration of each training will be one hour, the frequency of training will be twice a week for three months.
The genetic variations observed in most advanced cancers decrease the effectiveness of many anti-cancer agents through the development of drug resistance. Therefore, alternative approaches to the direct targeting of cancer cells are urgently needed. Bavituximab is the generic name for a chimeric (human/murine) monoclonal antibody directed against aminophospholipids. Bavituximab is Peregrine's first investigational product under its anti-phospholipid therapy technology platform. Anti-phospholipid therapy is a novel approach to treating cancer. It is based on the finding that aminophospholipids, which are basic components of the inner surface of cells become externally exposed in response to certain disease states such as cancer. Laboratory and animal studies have demonstrated that bavituximab specifically targets cancer cells and inhibits tumor growth in a variety of experimental cancer models. This study will examine the safety and tolerability of bavituximab when administered to patients with advanced solid tumor cancers that are unresponsive to current therapies. Cohorts of 6 patients each will be treated at the starting dose of 0.1 mg bavituximab per kilogram body weight (0.1 mg/kg). Successive patient cohorts will receive 0.3, 1.0 and 3.0 mg/kg of bavituximab. Patients will be followed for a total of 56 days. Patients who demonstrate an objective tumor response will be offered further bavituximab treatment on an extension protocol.
Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
The essential role of interleukin 7 (IL-7) signaling via its receptor (IL-7Rα; CD127) in T cell development and function has been well documented. However, CD127 expression and function in myeloid cells, including monocytes, are less clear, especially in mice. In the present study we report an inducible CD127 expression in mouse monocytes/macrophages. This induction is dependent on the presence of other immune cells, highlighting that regulation of CD127 expression on monocytes differs in mice and humans. We demonstrate that CD127 is functional, as IL-7 downregulated its expression. We also saw decreased CD127 expression during inflammation in vivo. Overall, upregulation of CD127 expression in vitro and its downregulation in vivo confirm that CD127 is an inducible marker on mouse monocyte/macrophage cells, in contrast to findings recently published by others. Characterizing the role of CD127 signaling in myeloid cells in inflammatory disorders would be worthwhile in future study.
Background and Objectives: The aim of this study was to investigate the efficacy of a single preoperative dose of deflazacort on pain, swelling, and trismus after impacted lower third molar surgery. Materials and Methods: This randomised, prospective, double-blind, split-mouth clinical study included 26 healthy individuals with bilaterally impacted lower third molars. Group 1 was given a placebo (single-dose vitamin C tablet), and group 2 was given a single 30 mg dose of deflazacort 1 h prior to surgery. Pain was evaluated using the visual analogue scale for 1 week postoperatively. Oedema (in mm) and trismus (in mm) were evaluated preoperatively and on postoperative days 2 and 7. The Mann-Whitney U test was applied for group analyses. p values < 0.05 were considered statistically significant. Results: Postoperative pain scores were significantly lower in the deflazacort group at the 6th and 12th hours after surgery (p < 0.05). There were no significant differences in trismus between the groups at any time point (p > 0.05). There was less oedema in the deflazacort group on postoperative days 2 and 7, without any statistically significant difference (p > 0.05). Conclusions: A single preoperative dose of 30 mg deflazacort was found to be clinically effective in reducing pain and oedema after extraction of impacted lower third molars.
Obesity is a pediatric epidemic that is more prevalent in children with developmental disabilities. We hypothesize that soy protein-based diets increase weight gain and alter neurobehavioral outcomes. Our objective herein was to test matched casein- and soy protein-based purified ingredient diets in a mouse model of fragile X syndrome, Fmr1KO mice. The experimental methods included assessment of growth; 24-7 activity levels; motor coordination; learning and memory; blood-based amino acid, phytoestrogen and glucose levels; and organ weights. The primary outcome measure was body weight. We find increased body weight in male Fmr1KO from postnatal day 6 (P6) to P224, male wild type (WT) from P32-P39, female Fmr1KO from P6-P18 and P168-P224, and female Fmr1HET from P9-P18 as a function of soy. Activity at the beginning of the light and dark cycles increased in female Fmr1HET and Fmr1KO mice fed soy. We did not find significant differences in rotarod or passive avoidance behavior as a function of genotype or diet. Several blood-based amino acids and phytoestrogens were significantly altered in response to soy. Liver weight was increased in WT and adipose tissue in Fmr1KO mice fed soy. Activity levels at the beginning of the light cycle and testes weight were greater in Fmr1KO versus WT males irrespective of diet. DEXA analysis at 8-months-old indicated increased fat mass and total body area in Fmr1KO females and lean mass and bone mineral density in Fmr1KO males fed soy. Overall, dietary consumption of soy protein isolate by C57BL/6J mice caused increased growth, which could be attributed to increased lean mass in males and fat mass in females. There were sex-specific differences with more pronounced effects in Fmr1KO versus WT and in males versus females.
Sealing and filling compositions for use in filling and/or sealing a root canal. The sealer and filler compositions include a polymerizable material that shrinks when polymerized. The composition also includes a gas releasing component that at least partially offsets the shrinkage caused by polymerization of the polymerizable material. The gas releasing component offsets polymerization shrinkage by creating tiny gas bubbles in the polymeric material, which causes expansion. The gas releasing component can be an acid and a base such as citric acid and sodium bicarbonate, which when mixed give off carbon dioxide. The composition can also include a dispersing agent to disperse the gas bubbles throughout the composition.
Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
NEW MATERIAL:The isoquinolinesulfonyl compound of formulaI(R1 is H or 1-10C alkyl; R2 is 1-10C alkyl, aryl or aralkyl) and its acid addition salt. EXAMPLE:1-(5-Isoquinolinesulfonyl)-2,5-dimethylpiperazine. USE:A vasodilator, cerebral circulation improving agent, remedy for stenocardia, and preventive and remedy for thrombosis of cerebral and cardiac vessel. It has strong smooth muscle relaxing and blood flow rate increasing activities. PROCESS:The compound of formulaIis prepard e.g. by reacting 5-isoquinolinesulfonic acid chloride of formula II with the piperazine or derivative of formula III in the presence of an acid acceptor such as sodium bicarbonate, etc.
Using their existing technology, Oscar is employing a randomized controlled trial among their physicians to improve their engagement and relationships with patients. The goal will be to test and refine patient pings as a provider engagement tool, with an eye toward using it within the broader approach to high-risk patients as well. The Penn team is helping to design the intervention, which includes helping with determining what the three arms will be and randomizing physicians and practice sites. They will implement a three-arm trial with the first arm being usual care (no pings), the second arm being the intervention of information, and the third arm being the intervention of information and financial incentives. In the two intervention groups, providers will be sent patient pings after a patient experiences a trigger event. This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patients doctors including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. In the third arm, physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians will receive an incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event. This bonus payment will be paid to physicians uncoupled from usual reimbursement as a separate bonus check to increase salience. No pings will be sent to the physicians for the patients randomized to arm 1: usual care.
BACKGROUND: Community-acquired pneumonia (CAP) patients with chronic obstructive pulmonary disease (COPD) have higher disease severity and mortality compared to those without COPD. However, deep investigation into microbiome distribution of lower respiratory tract of CAP with or without COPD was unknown.
METHODS: So we used metagenomic next generation sequencing (mNGS) to explore the microbiome differences between the two groups.
RESULTS: Thirty-six CAP without COPD and 11 CAP with COPD cases were retrieved. Bronchoalveolar lavage fluid (BALF) was collected and analyzed using untargeted mNGS and bioinformatic analysis. mNGS revealed that CAP with COPD group was abundant with Streptococcus, Prevotella, Bordetella at genus level and Cutibacterium acnes, Rothia mucilaginosa, Bordetella genomosp. 6 at species level. While CAP without COPD group was abundant with Ralstonia, Prevotella, Streptococcus at genus level and Ralstonia pickettii, Rothia mucilaginosa, Prevotella melaninogenica at species level. Meanwhile, both alpha and beta microbiome diversity was similar between groups. Linear discriminant analysis found that pa-raburkholderia, corynebacterium tuberculostearicum and staphylococcus hominis were more enriched in CAP without COPD group while the abundance of streptococcus intermedius, streptococcus constellatus, streptococcus milleri, fusarium was higher in CAP with COPD group.
CONCLUSIONS: These findings revealed that concomitant COPD have an mild impact on lower airway microbiome of CAP patients.
Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute respiratory distress syndrome or fatal outcome have been reported in clinical trials with KADCYLA. Signs and symptoms include dyspnea, cough, fatigue, and pulmonary infiltrates.

In patients with MBC, pneumonitis was reported at an incidence of 0.8% (7 out of 884 treated patients), with one case of Grade 3 pneumonitis. The overall incidence of pneumonitis was 1.2% in EMILIA. In KATHERINE, pneumonitis was reported at an incidence of 0.9% (7 out of 740 patients treated with KADCYLA), with one case of Grade 3 pneumonitis.

Radiation pneumonitis was reported at an incidence of 1.6%, with 2 cases of Grade 3 radiation pneumonitis [see Adverse Reactions (6.1)].

Permanently discontinue treatment with KADCYLA in patients diagnosed with ILD or pneumonitis. For patients with radiation pneumonitis in the adjuvant setting, KADCYLA should be permanently discontinued for Grade ≥ 3 or for Grade 2 not responding to standard treatment [see Dose Modifications (2.3)].

Patients with dyspnea at rest due to complications of advanced malignancy, co-morbidities, and receiving concurrent pulmonary radiation therapy may be at increased risk of pulmonary toxicity.
A folate-metal ion composition, a folate-metal ion hydrogel, a sun-screening agent containing the hydrogel and use thereof in ultraviolet absorption. After a folate aqueous solution and a metal ion aqueous solution have been mixed, folate and the metal ions are cross-linked to form a solution, gel or suspension containing a reticular hydrogel, and the metal ions are coordinated with folate molecules. The folate-metal ion hydrogel has good biocompatibility, has significant advantages in the field of biological applications, and also provides a new nutritional supplement form. The sun protection effect of the folate-metal ion hydrogel and folate are almost constant. The folate-metal ion hydrogel has good safety, high reliability and stable chemical properties, and is refreshing after being prepared into a sun-screening agent, having good user experience. The preparation method for the folate-metal ion hydrogel is simple and convenient, controllable and adjustable, and can satisfy different production requirements and consumer demands.
PURPOSE: A composition for preventing or treating immunization diseases including P53 is provided to suppress inflammatory cytokine IL-17 which causes the immunization diseases. CONSTITUTION: A composition for preventing or treating immunization diseases includes P53 as an active ingredient. The P53 has the activity of preventing or treating the immunization diseases through the formation inhibition of the inflammatory cytokine. The inflammatory cytokine is IL-17. The composition additionally includes substances for promoting the express of the p53 or for promoting the activity of protein. The composition for preventing or treating includes polynucleotide which codes the P53. The polynucleotide ciphering the p53 protein is provided in a recombinant vector type which is connected to a vector which expresses the same. The expression vector which expresses the P53 protein is a non-virus vector or a viral vector.
Orally administrable pharmaceutical dosage units having a shape such that its most stable position on a horizontal flat surface is tilted. The units may be tablets, capsules, cachets, wafers, lozenges or analogous confections and candies. For the dosage unit to tilt it has a main body which has projections on its surfaces capable of acting as fulcra. Preferably the dosage units are tablets which have dome or pyramidal shaped projections centrally located on its surfaces. The dosage units are prepared according to the standard procedures of the pharmaceutical art. In the case of tablets, the granulation is compressed employing the appropriately shaped punches and dies.
Human Experience

No cases of overdose were reported in premarketing studies with UZEDY.

In premarketing experience with oral risperidone, there were eight reports of acute risperidone overdosage with estimated doses ranging from 20 to 300 mg and no fatalities. In general, reported signs and symptoms were those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. One case, involving an estimated overdose of 240 mg, was associated with hyponatremia, hypokalemia, prolonged QT, and widened QRS. Another case, involving an estimated overdose of 36 mg, was associated with a seizure.

Postmarketing experience with oral risperidone included reports of acute overdosage with estimated doses of up to 360 mg. In general, the most frequently reported signs and symptoms are those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. Other postmarketing adverse reactions related to oral risperidone overdose include prolonged QT interval and convulsions. Torsade de pointes has been reported in association with combined overdose of oral risperidone and paroxetine.

Management of Overdosage

There is no specific antidote to risperidone. Provide supportive care including close medical supervision and monitoring. Treatment should consist of general measures employed in the management of overdosage with any drug. Consider the possibility of multiple drug overdosage. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs.

Consider contacting the Poison Help Line (1-800-222-1222) or medical toxicologist for additional overdosage management recommendations.
To provide a new catenin concerning with the function of cell-cell adhesion, a gene encoding said catenin, and a use of said gene. Isolated neural  alpha -catenin. A gene encoding neural  alpha -catenin. A method of producing neural  alpha -catenin by the method of genetic engineering. A method of controlling the function of cell-cell adhesion by using said gene. Antibodies capable of recognizing neural  alpha -catenin. Amino acid sequense of said neural  alpha -catenin and nucleotide sequence of said gene are also determined.
The invention discloses a processing technology of prepared fleeceflower root, and belongs to the technical field of traditional Chinese medicine processing. The processing technology includes preparing black bean milk, moistening, steaming, drying, and the like. Black bean is adopted as an auxiliary material. The water using amount, decocting time and moistening time during preparation are provided with definite process testified parameters. The steaming step adopts a vacuum steaming manner, and steaming time and temperature are provided with definite parameters. Traditional processing effects are achieved. Compared with traditional processing, the processing technology is more scientific, steaming is simplified, the production period is shortened, the cost is saved, and pilot plant tests prove that products produced by the processing technology are stable in quality, uniform and effective. The processing technology is suitable for large-scale industrial production of the prepared fleeceflower root.
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
FIELD: cosmetology, in particular, hair shampoos. SUBSTANCE: agent contains biologically active components in the form of complex from water-alcoholic-glycerine extracts of drug, wild and cultivated plants. They are: common nettle, common onion, oat with complete or incomplete set from one component or more, including, birch leaves, yarrow, hawthorn fruits, mustard, agrimony, goosefoot, pumpkin, couch grass, levzea of safflower species, mullein, coltsfoot, and branches, fruits and leaves of plants of elaegnus family. Biologically active and fragrant substances used as natural aromatizer, are additionally introduced in form of water-alcoholic-glycerine extracts of wormwood with complete or incomplete set from one component or more, including thyme, sweetflag, origanum, iris roots, melissa and leafy shoots of black currant. Ratio of components is indicated in shampoos formula. EFFECT: higher biological activity. 1 tbl